Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Making innate sense of mRNA vaccine adjuvanticity
Kouji Kobiyama, Ken J. Ishii
Nature Immunology (2022) Vol. 23, Iss. 4, pp. 474-476
Open Access | Times Cited: 71

Showing 1-25 of 71 citing articles:

Innate immune mechanisms of mRNA vaccines
R Verbeke, Michael J. Hogan, Karin Loré, et al.
Immunity (2022) Vol. 55, Iss. 11, pp. 1993-2005
Open Access | Times Cited: 215
Challenges in developing personalized neoantigen cancer vaccines
Peter D. Katsikis, Ken J. Ishii, Christopher Schliehe
Nature reviews. Immunology (2023) Vol. 24, Iss. 3, pp. 213-227
Closed Access | Times Cited: 74
Nanotechnology-based mRNA vaccines
Shuying Chen, Xiangang Huang, Yonger Xue, et al.
Nature Reviews Methods Primers (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 70
Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability
Lizhou Zhang, Kunal R. More, Amrita Ojha, et al.
npj Vaccines (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 67
Knife’s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines
Jisun Lee, Matthew C. Woodruff, Eui Ho Kim, et al.
Experimental & Molecular Medicine (2023) Vol. 55, Iss. 7, pp. 1305-1313
Open Access | Times Cited: 50
mRNA vaccines: The future of prevention of viral infections?
Piotr Rzymski, Agnieszka Szuster−Ciesielska, Tomasz Dzieciątkowski, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 2
Closed Access | Times Cited: 46
Chemically Modified Platforms for Better RNA Therapeutics
Yesi Shi, Xueyan Zhen, Yiming Zhang, et al.
Chemical Reviews (2024) Vol. 124, Iss. 3, pp. 929-1033
Closed Access | Times Cited: 39
A comprehensive comparison of DNA and RNA vaccines
Chunxi Wang, Fan Yuan
Advanced Drug Delivery Reviews (2024) Vol. 210, pp. 115340-115340
Closed Access | Times Cited: 16
Vaccine adjuvants to engage the cross-presentation pathway
Woo‐Jong Lee, M. Suresh
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 61
Research progress on circular RNA vaccines
Yu Bai, Dong Liu, Qian He, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 32
Adjuvant physiochemistry and advanced nanotechnology for vaccine development
Hongze Ren, Wencong Jia, Yujie Xie, et al.
Chemical Society Reviews (2023) Vol. 52, Iss. 15, pp. 5172-5254
Closed Access | Times Cited: 30
Nanoparticle-Based Adjuvants and Delivery Systems for Modern Vaccines
Brankica Filipić, Ivana Pantelić, Ines Nikolić, et al.
Vaccines (2023) Vol. 11, Iss. 7, pp. 1172-1172
Open Access | Times Cited: 29
Cancer vaccines in the clinic
Morgan E. Janes, Alexander P. Gottlieb, Kyong Soo Park, et al.
Bioengineering & Translational Medicine (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 29
Understanding nucleic acid sensing and its therapeutic applications
Ling-Zu Kong, Seok‐min Kim, Chunli Wang, et al.
Experimental & Molecular Medicine (2023) Vol. 55, Iss. 11, pp. 2320-2331
Open Access | Times Cited: 28
Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery
Geonhee Han, Dahye Noh, Hokyung Lee, et al.
Advanced Drug Delivery Reviews (2023) Vol. 199, pp. 114973-114973
Open Access | Times Cited: 27
Trained immunity: Target for prophylaxis and therapy
Athanasios Ziogas, Mariolina Bruno, Roy van der Meel, et al.
Cell Host & Microbe (2023) Vol. 31, Iss. 11, pp. 1776-1791
Open Access | Times Cited: 26
High‐Precision Synthesis of RNA‐Loaded Lipid Nanoparticles for Biomedical Applications
Hanjin Seo, Leekang Jeon, Jaeyeong Kwon, et al.
Advanced Healthcare Materials (2023) Vol. 12, Iss. 13
Closed Access | Times Cited: 24
A lipid nanoparticle platform incorporating trehalose glycolipid for exceptional mRNA vaccine safety
Seo‐Hyeon Bae, Soyeon Yoo, Ji Sun Lee, et al.
Bioactive Materials (2024) Vol. 38, pp. 486-498
Open Access | Times Cited: 11
Adjuvantation of a SARS-CoV-2 mRNA vaccine with controlled tissue-specific expression of an mRNA encoding IL-12p70
Byron Brook, Valérie Duval, Soumik Barman, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 757
Closed Access | Times Cited: 9
mRNA Vaccines Contribute to Innate and Adaptive Immunity to Enhance Immune Response In Vivo
Qiannan Cao, Huapan Fang, Huayu Tian
Biomaterials (2024) Vol. 310, pp. 122628-122628
Closed Access | Times Cited: 8
Advanced technologies for the development of infectious disease vaccines
Akash Gupta, Arnab Rudra, Kaelan Reed, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 12, pp. 914-938
Closed Access | Times Cited: 7
Resolving adjuvant mode of action to enhance vaccine efficacy
Joanna L. Turley, Ed C. Lavelle
Current Opinion in Immunology (2022) Vol. 77, pp. 102229-102229
Open Access | Times Cited: 36
Clinical Pharmacokinetics of Approved RNA Therapeutics
Seong Jun Jo, Soon Uk Chae, Chae Bin Lee, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 1, pp. 746-746
Open Access | Times Cited: 19
mRNA vaccine designs for optimal adjuvanticity and delivery
Yuki Mochida, Satoshi Uchida
RNA Biology (2024) Vol. 21, Iss. 1, pp. 1-27
Open Access | Times Cited: 5
A-910823, a squalene-based emulsion adjuvant, enhances robust and broad immune responses of quadrivalent influenza vaccine in ferrets
Masayuki Hashimoto, Kenichiro Tsujii, Hitomi Nakajima-Yoshida, et al.
Vaccine (2025) Vol. 49, pp. 126780-126780
Open Access
Page 1 - Next Page

Scroll to top